(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 204K | -30% |
Gross Profit | 133K | -24% |
Cost Of Revenue | 71K | -39% |
Operating Income | -3MM | +20% |
Operating Expenses | 3.1MM | - |
Net Income | -5.6MM | - |
R&D | 903K | -29% |
G&A | 2.2MM | +59% |
Amortization | 19K | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
POTOMAC, Md., April 16, 2024--IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two.
POTOMAC, Md., April 09, 2024--IGC Pharma Adds Advisor in Artificial Intelligence
POTOMAC, Md., March 26, 2024--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
POTOMAC, Md., March 20, 2024--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
POTOMAC, Md., March 20, 2024--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
POTOMAC, Md., March 12, 2024--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline.
POTOMAC, Md., February 28, 2024--Promising Results - TGR-63 Enhances Memory in Alzheimer's Mouse Model
POTOMAC, Md., February 23, 2024--IGC Ascendiant Coverage
POTOMAC, Md., February 17, 2024--IGC Pharma Reports Third Quarter Fiscal 2024 Results
POTOMAC, Md., February 01, 2024--TGR-63 Reduces Agitation in Alzheimer's Mouse Model